Skip to main content
Figure 2 | Arthritis Research & Therapy

Figure 2

From: Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study

Figure 2

Number of lung segments with high-resolution computed tomography ground-glass opacities and honeycombing in all patients at baseline and at 6 months. Number of lung segments with high-resolution computed tomography ground-glass opacities (A) and honeycombing (B) in all 26 patients at baseline and at 6 months (T6), and in the subgroups of patients classified as improved, stabilized, and worsened after 6 months of treatment with imatinib (C). (A), (B) Data expressed as median with interquartile ranges. (C) Data expressed as absolute numbers of lung segments.

Back to article page